In-Vitro Immunomodulatory Activity and Thrombolytic Potential of Kabasura Kudineer (KSK), an Official Siddha Polyherbal Formulation

Abstract

Coronavirus disease 2019 (COVID‐19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), a pandemic, which has led to the spread of mortality and morbidity all over the globe. In this dire situation, there is an urgent requirement for the development and immediate dissemination of treatment against COVID‐19. The traditional medicine system of Siddha can be utilized as preventive care to boost the immune system. The vast treasure of knowledge found in Siddha medicine can help in the betterment of humankind. Kabasura Kudineer (KSK) is from the ancient times present as an immune-boosting agent against several diseases. The present experimental setup to investigate the immunomodulatory and thrombolytic potential of KSK. The in vitro immunomodulatory models of phagocytosis of Candida albicans assay and nitro blue tetrazolium have demonstrated that KSK is giving better results compared with the controls (pooled serum, lipopolysaccharide, and streptokinase). The KSK at the concentrations of 12.5, 25, 50, and 100 μg/ml showed % immune-stimulations of 12.40 %, 20.81 %, 33.53 %, 43.20 % and for NBT showed 19.00 %, 25.50 %, 64.00 %, 71.00 % respectively. And similarly, the thrombolytic activity showed 50 and 100 μg/ml concentration showed 43.83 %, 71.83 % clot lysis respectively; and the control value for the streptokinase showed 83.78 %. Hence, it can be confirmed that KSK has immunomodulatory and thrombolytic properties in in vitro models, although the in vivo and the identification of KSK are to be discovered.